Is the price fair?
What DMRA's price assumes
Damora Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 213× revenue.
213
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.74
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 1.74
- EV / EBIToperating margin −3312%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $1.31B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.